Aptinyx Inc traded at $0.40 this Monday September 26th, decreasing $0.02 or 4.50 percent since the previous trading session. Looking back, over the last four weeks, Aptinyx Inc lost 0.83 percent. Over the last 12 months, its price fell by 83.96 percent. Looking ahead, we forecast Aptinyx Inc to be priced at 0.41 by the end of this quarter and at 0.37 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
Daily Change

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Peers Price Day Year
Daiichi Sankyo 3,995.00 -50.00 -1.24% 29.54%
Acadia Pharmaceuticals 16.47 -0.28 -1.67% -5.40%
Acorda Therapeutics 0.29 0.004 1.36% -93.87%
Biogen 196.07 -1.71 -0.86% -31.59%
Cara Therapeutics 8.51 0.03 0.35% -46.95%
Halozyme Therapeutics 38.51 -0.31 -0.80% -4.08%
Ionis Pharmaceuticals 41.83 -1.40 -3.24% 16.62%
Intra Cellular Therapies 42.98 -0.53 -1.22% 13.82%
Eli Lilly 308.44 -3.02 -0.97% 36.24%
Marinus Pharmaceuticals 6.58 -0.49 -6.87% -46.76%
Neurocrine Biosciences 101.65 -1.85 -1.79% 7.10%
Novartis 73.98 -0.38 -0.51% -3.50%
Ultragenyx Pharmaceutical 40.27 -1.23 -2.96% -54.58%
UCB 68.80 -0.64 -0.92% -27.35%
Vertex Pharmaceuticals 280.05 -3.40 -1.20% 52.69%

Aptinyx Inc
Aptinyx Inc. is a clinical-stage biopharmaceutical company that is focused on the discovery, development and commercialization of synthetic small molecules for the treatment of brain and nervous system disorders. The Company has a platform for discovering compounds that work through a mechanism that is the modulation of the N-methyl-D-aspartate receptors (NMDAr), which are focused on brain and nervous system functions. The Company’s lead product candidate, NYX-2925 is in Phase II clinical development for the treatment of chronic pain and enables synaptic plasticity in the brain, a mechanism that is differentiated from any therapy used for the treatment of chronic pain. Its products also include NYX-783, which is in Phase II clinical development for the treatment of post-traumatic stress disorder (PTSD), and NYX-458 is in Phase II clinical development for the treatment of cognitive impairment associated with Parkinson’s disease and Lewy body dementia.